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Abstract
Background: Expression of Dkk-3, a secreted putative tumor suppressor, is altered in age-related proliferative
disorders of the human prostate. We now investigated the suitability of Dkk-3 as a diagnostic biomarker for
prostate cancer (PCa) in seminal plasma (SP).
Methods: SP samples were obtained from 81 patients prior to TRUS-guided prostate biopsies on the basis of
elevated serum prostate-specific antigen (PSA; > 4 ng/mL) levels and/or abnormal digital rectal examination. A
sensitive indirect immunoenzymometric assay for Dkk-3 was developed and characterized in detail. SP Dkk-3 and
PSA levels were determined and normalized to total SP protein. The diagnostic accuracies of single markers
including serum PSA and multivariate models to discriminate patients with positive (N = 40) and negative (N = 41)
biopsy findings were investigated.
Results: Biopsy-confirmed PCa showed significantly higher SP Dkk-3 levels (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg; p
= 0.026). Diagnostic accuracy (AUC) of SP Dkk-3 levels (0.633) was enhanced in multivariate models by including
serum PSA (model A; AUC 0.658) or both, serum and SP PSA levels (model B; AUC 0.710). In a subpopulation with
clinical follow-up > 3 years post-biopsy to ensure veracity of negative biopsy status (positive biopsy N = 21;
negative biopsy N = 25) AUCs for SP Dkk-3, model A and B increased to 0.667, 0.724 and 0.777, respectively.
Conclusions: In multivariate models to detect PCa, inclusion of SP Dkk-3 levels, which were significantly elevated
in biopsy-confirmed PCa patients, improved the diagnostic performance compared with serum PSA only.
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Background
The secreted glycoprotein Dickkopf-related protein 3
(Dkk-3) is the most divergent member of the human
Dickkopf family [1,2] that, in contrast to other family
members, does not modulate Wnt signaling [3,4]. Dkk-3
has been proposed to represent a novel tumor suppres-
sor since gene expression is downregulated in various
tumor cells [5-9] and hypermethylation of its promoter
correlates with cancer occurrence [10,11].
Our previous results indicated a possible link between
Dkk-3 expression and age-associated processes in the
human prostate. Serial analysis of gene expression
(SAGE) of human prostate basal epithelial cells revealed
specific induction of DKK3 gene during cellular
senescence in vitro [12]. Moreover, Dkk-3 was found
downregulated in vivo in prostate epithelium of patients
suffering from the age-related prostatic conditions
benign prostatic hyperplasia (BPH) and prostate cancer
(PCa), with this downregulation counterbalanced by
increased Dkk-3 protein expression in the endothelial
cells of the tumor neovasculature [13].
This study was intended to assess changes in Dkk-3
content in prostatic fluid in these two conditions and its
potential as a diagnostic marker for PCa. Since prostatic
secretions constitute approximately 30% of seminal fluid
volume [14], of all readily obtainable body fluids, ejacu-
late supernatant (seminal plasma; SP) reflects the con-
temporary status of the prostate best. We previously
demonstrated that Dkk-3 could be detected in SP in
apparently healthy donors at concentrations of 2.59 ±
0.41 nmol/L (range 1.62-5.2 5n m o l / L )t h a tw a sh i g h e r
that plasma Dkk-3 levels (1.22 ± 0.04 nmol/L) but much
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± 1.3 nmol/L) [15]. SP Dkk-3 and SP prostate-specific
antigen (PSA) levels were analyzed from 81 patients
who underwent transrectal ultrasound (TRUS)-guided
prostate biopsies due to elevated serum PSA levels and/
or abnormal digital rectal examination (DRE). Ejaculate
specimens were obtained prior to biopsy. SP Dkk-3 and
SP PSA levels were compared, alone and in combination
w i t hs e r u mP S A ,t ot h ed i a g n o s t i cp e r f o r m a n c eo f
serum PSA alone to detect PCa in univariate and multi-
variate models.
Methods
Subjects - SP samples
Eighty-one patients who were to undergo TRUS-guided
biopsies because they had an abnormal serum PSA level
(> 4 ng/mL) and/or abnormal DRE were recruited into
the study from the outpatient department or from pri-
vate rooms of urologists at Royal Brisbane and Women’s
Hospital (RBWH) between 1996 and 2009. Of this
group, 40 men were confirmed to have cancer and 41
men had negative biopsies. Subsequently, patients with
negative TRUS biopsy findings were followed with PSA
and DREs and with further TRUS biopsies as indicated
in selected cases to ensure the veracity of the TRUS-
negative findings. A subgroup of 25 patients with nega-
tive and 21 with positive biopsy had a clinical follow-up
of > 3 years (collected between 1996 and 08/2007). This
subset of patients had been selected from our archive
because we were as sure as we can be that those desig-
nated not to have prostate cancer were true negatives.
All SP specimens were obtained before biopsy and treat-
ment and after giving informed consent. Patients col-
lected ejaculate via masturbation into urine collection
jars containing 20 mL of Hanks balanced salt solution
in the morning at home and brought them to the hospi-
tal within 2 hours of collection (without freezing or
cooling, i.e. at temperatures from ~5-25°C) where they
were processed within 15 minutes after arrival. Samples
were layered over 10 mL of 64% isotonic Percoll (Amer-
sham Biosciences) and centrifuged at 2200 rpm for 30
min at 4°C. The ejaculate supernatants (SP) were
removed, aliquoted and stored at -70°C until further
processing (as reported previously [16,17]). The study
had the approval of the ethics committees of the RBWH
and University of Queensland.
Establishment of a sensitive Dkk-3 assay
A series of six monoclonal Antibodies (mAb) INN
(sbruck)-Dkk3-1 to INN-Dkk3-6 as previously described
[18] and an affinity purified polyclonal goat anti Dkk-3
antibody (R&D Systems Cat.#AF1118) were character-
ized by radioimmunoassays (RIA) according to affinity,
molecular epitope localization and specificity with native
(untagged) Dkk-3 and the commercially available homo-
logous proteins Dkk-1, Dkk-4 and Sgy-1 (R&D Systems)
as described elsewhere [18]. The antibodies with the
highest affinity towards Dkk-3 (mAb INN-Dkk3-1 and
the goat polyclonal antibody) showed no significant
reactions towards the homologous proteins Dkk-1 and
Dkk-4 however the polyclonal antibody when tested at a
concentration of 5 μg/mL reacted slightly with the
homologous protein Sgy-1 (Figure 1A). In competitive
RIA to assess cross-reactivity increasing concentrations
of Dkk-3 or Sgy-1 competed with
125I labeled Dkk-3
(approximately 25,000 cpm) for binding to 30 ng of
polyclonal goat anti Dkk-3 antibody in 300 μLt o t a l
reaction volume (1% BSA/PBS) overnight at 4°C. Separa-
tion of bound from free tracer was performed as
described [18], and cross-reactivity towards Sgy-1 was
determined to be 0.025% (Figure 1B). Epitope mapping
by polypeptide screening revealed localization of the
INN-Dkk3-1 epitope in the N-terminal region (aminoa-
cids 21-147) while the polyclonal antibody predomi-
nantly reacted with the C-terminal region (aminoacids
200-350; data not shown).
A sensitive sandwich immunoradiometric assay
(IRMA) was established with mAb INN-Dkk3-1 (coating
antibody) and the
125l labeled goat polyclonal antibody
(R&D Systems) as described previously [19]. All samples
were run in duplicate and results calculated from specific
mean signal (mean - zero standard). Native i.e. untagged
Dkk-3 purified via HPLC (anion exchange followed by
size exclusion chromatography) from conditioned media
of stably transfected LNCaP cells [13] was used as stan-
dard. Cross-reactivity was shown to be < 0.1% for Sgy-1
and < 0.01% for Dkk-1 and Dkk-4 (Figure 1C).
To increase sensitivity and to allow higher sample
throughput, the assay was commuted to a 96-well plate
based indirect immunoenzymometric assay (IEMA)
described previously [18] by replacement of the
125l
labeled antibody by a biotinylated variant of the polyclo-
nal goat anti Dkk-3 antibody (R&D Systems Cat.
#BAF1118). All samples were run in duplicate and
results were calculated from specific mean signal (mean
- zero standard). Recovery was 92% and sensitivity 1
pmol/L. The intra- and inter-assay variances (%CV) at a
protein concentration of 40 pmol/L were 11% and 13%,
respectively.
PSA and total protein measurements
Serum PSA was assayed using a fluoroimmunoenzy-
metric two-site assay (Medics 1200 Dx AIA, Tosoh
Corp.). SP PSA values were analyzed by the ADVIA
Centaur PSA assay (Siemens Healthcare Diagnostics) at
a dilution of 1:5000. SP Dkk-3 and PSA levels were nor-
malized to total protein levels determined by the Pierce
BCA Protein Assay Kit (Thermo Scientific).
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Figure 1 Establishment of the Dkk-3 assay. mAb INN-Dkk3-1 and goat polyclonal antibody (R&D Systems) showed no significant cross-
reactivities with homologous proteins Dkk-1 and Dkk-4. The polyclonal antibody (5 μg/mL) showed weak reactivity for the homologous protein
Sgy-1 in a direct binding RIA (A). In a competitive RIA the goat polyclonal antibody showed a cross-reactivity (XR) of 0.025% for Sgy-1 (B). A
standard curve from 0.25 pmol/L - 250 pmol/L Dkk-3 in comparison to the homologous proteins at a concentration of 1000 pmol/L revealed
cross-reactivities in the sandwich assay of < 0.01% (C). The established sandwich assay had a recovery of 92% and sensitivity of 1 pmol/L. The
intra- and inter-assay variances (%CV) at a protein concentration of 40 pmol/L were 11% and 13%, respectively.
Zenzmaier et al. Journal of Translational Medicine 2011, 9:193
http://www.translational-medicine.com/content/9/1/193
Page 3 of 7Statistical analyses
Assay sensitivity was defined as the mean signal of non-
specific binding (NSB = zero standard) plus three stan-
dard deviations (NSB + 3SD). Percent coefficient of var-
iation (%CV) was used as a measure of dispersion about
the mean and expressed SD as a percentage of the
mean.
Statistical differences among groups were calculated
by Mann-Whitney test. Multivariate logistic regression
was used to analyze correlations between investigated
markers and PCa diagnostic status and the quality of
the obtained models were estimated by Hosmer-Leme-
show goodness-of-fit tests. The diagnostic performance
of the tested variables and the multivariate models was
evaluated by plotting the receiver-operating characteris-
tics (ROC) curve and calculating the area under the
ROC curve (AUC). Associations between the investi-
gated markers, age at time of the ejaculation specimen
and Gleason score were evaluated using Pearson correla-
tion analysis or Spearman’s rank correlation analysis
when data belonged to categorial variables.
All statistical analyses were performed using PASW
Statistics 18 (IBM).
Results
The characteristics of all 81 patients and the 46 patients
with a follow-up of > 3 years are summarized in Table
1. Serum PSA as well as SP Dkk-3 levels (characteristics
of the sandwich assay depicted in Figure 1) were found
significantly higher in the PCa confirmed patients in
both, the all patients cohort as well as the > 3 year fol-
low-up subgroup. SP PSA levels were although also
slightly elevated not significantly different. A multivari-
ate logistic regression model based on serum PSA and
SP Dkk-3 levels (model A) significantly discriminated
negative from positive biopsies in both cohorts (Table 2;
all patients: p = 0.007, predictive accuracy = 64.2%; fol-
low-up > 3 years: p = 0.007, predictive accuracy = 73.9).
Although not significantly different between patients
with positive and negative biopsies, inclusion of SP PSA
(model B) increased the predictive accuracy of the
model for the cohort of all patients.
T h ed i a g n o s t i cp e r f o r m a n ces of the univariate test
variables and the multivariate models were determined
by ROC analyses (Figure 2 and Table 3). AUCs, as a
measure for diagnostic accuracy, for serum PSA, SP
Dkk-3, SP PSA, model A and model B were 0.644,
0.633, 0.565, 0.658 and 0.710 in the cohort of all
patients and 0.696, 0.667, 0.562, 0.724 and 0.777 in
patients with > 3 years clinical follow-up, respectively,
showing that the multiplex models had higher AUCs in
both cohorts compared with the single markers and
model B higher accuracy compared with model A.
Moreover, except for SP PSA all AUCs where higher in
the > 3 year follow-up cohort.
Lastly, correlations between the individual markers,
a g ea n db i o p s yG l e a s o ns c o r ew e r ea n a l y z e d( T a b l e4 ) .
SP Dkk-3 and SP PSA were found independent for
serum PSA, Age and Gleason score whereas serum PSA
levels correlated with Gleason score (all patients: p =
0.034; > 3 years follow-up: p =0 . 0 2 4 )b u tn o tw i t ha g e .
Interestingly SP Dkk-3 levels correlated with SP PSA
levels (all patients: p = 0.013) but this correlation was
Table 1 Characteristics of the study cohort.
all patients
Characteristic Negative biopsy Positive biopsy p value
Patients, N 41 40
Age*, yr 0.981
Mean ± SEM 61.0 ± 1.3 61.5 ± 1.3
Median (IQR) 62.5 (57.1 - 67.0) 61.9 (55.6 - 66.6)
serum PSA [ng/mL] 0.026
Mean ± SEM 7.5 ± 1.0 11.6 ± 1.9
Median (IQR) 6.2 (4.1 - 8.9) 7.3 (5.8 - 13.3)
SP Dkk-3 [fmol/mg]** 0.039
Mean ± SEM 69.2 ± 9.4 100.9 ± 12.3
Median (IQR) 55.7 (35.8 - 91.2) 74.5 (41.7 - 124.5)
SP PSA [μg/mg]** 0.317
Mean ± SEM 23.8 ± 3.3 28.0 ± 3.5
Median (IQR) 16.8 (8.1 - 35.9) 19.9 (10.8 - 42.5)
Biopsy Gleason score
≤ 66
72 6
≥ 88
clinical follow-up > 3 yr
Characteristic Negative biopsy Positive biopsy p value
Patients, N 25 21
Age*, yr 0.700
Mean ± SEM 63.1 ± 1.6 61.6 ± 2.3
Median (IQR) 64.0 (60.9 - 68.9) 60.5 (53.7 - 69.8)
serum PSA [ng/mL] 0.012
Mean ± SEM 8.0 ± 1.6 14.3 ± 3.3
Median (IQR) 6.2 (3.6 - 10.4) 9.2 (6.5 - 16.0)
SP Dkk-3 [fmol/mg]** 0.027
Mean ± SEM 56.3 ± 8.4 100.0 ± 16.6
Median (IQR) 49.6 (22.3 - 76.4) 76.3 (35.9 - 169.4)
SP PSA [μg/mg]** 0.474
Mean ± SEM 23.4 ± 4.5 27.4 ± 5.1
Median (IQR) 16.8 (7.3 - 40.1) 19.5 (12.7 - 35.0)
Biopsy Gleason score
≤ 63
71 4
≥ 84
SEM, standard error of the mean; IQR, interquartile range; PSA, prostate-
specific antigen; SP, seminal plasma; * at time of ejaculate specimen; ** per
total protein; p values determined by Mann-Whitney test.
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Page 4 of 7limited to patients with biopsy confirmed PCa (all
patients: p = 0.007; > 3 years follow-up: p = 0.026) while
no correlation was observed in patients with negative
biopsies (all patients: p = 0.301; > 3 years follow-up: p =
0.620).
Discussion
Serum PSA is currently the most widely used PCa
screening test, however, PSA is organ- but not disease-
specific, thus its value to predict PCa is limited and
there is a need for additional disease markers. We
consider SP as an ideal source to monitor pathological
changes in the prostate since it more directly reflects
local glandular production than other sources such as
peripheral blood. Moreover, SP donation is completely
non-invasive avoiding the discomfort and possible con-
cerns associated with prostate massage necessary to
obtain post-massage urine. Previously, we reported that
the inactive free:total PSA ratios in SP from men with
suspected PCa did not distinguish between those har-
boring malignant as opposed to benign disease [16]. The
present study was designed to assess changes in Dkk-3
Table 2 Multivariate logistic regression analyses to asses the predictive value in prostate cancer detection.
Cohort Variable b-coefficient OR 95% CI p-value Predictive accuracy % H-L p-value
all patients model A 0.007 64.2 0.979
serum PSA 0.071 1.074 0.997 - 1.157 0.06
SP Dkk-3 0.008 1.008 1.000 - 1.016 0.039
model B 0.007 69.1 0.737
serum PSA 0.07 1.072 0.996 - 1.002 0.063
SP Dkk-3 0.01 1.010 1.002 - 1.018 0.019
SP PSA 0.017 1.018 0.995 - 1.041 0.13
clinical follow-up > 3 yr model A 0.005 73.9 0.691
serum PSA 0.071 1.074 0.992 - 1.164 0.08
SP Dkk-3 0.014 1.015 1.002 - 1.027 0.02
model B 0.007 73.9 0.806
serum PSA 0.069 1.072 0.991 - 1.159 0.083
SP Dkk-3 0.016 1.016 1.004 - 1.029 0.012
SP PSA 0.018 1.018 0.988 - 1.049 0.238
OR, odds ration; CI, confidence intervall; H-L, Hosmer-Lemeshow test; PSA, prostate-specific antigen; SP, seminal plasma.
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Figure 2 Receiver operator characteristics (ROC) curves. ROC curves of serum prostate-specific antigen (PSA), seminal plasma (SP) Dkk-3 and
SP PSA levels and the multivariate models based on serum PSA and SP Dkk-3 (model A) or on all three individual markers (model B) for (A) the
entire cohort and (B) patients with > 3 years clinical follow-up.
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from malignant prostatic conditions in patients who
were to undergo TRUS-guided biopsy due to elevated
serum PSA (> 4 ng/mL) and/or abnormal DRE.
With the IEMA developed in our laboratory, SP Dkk-3
levels were found significantly higher in patients with
biopsy confirmed PCa (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/
mg). Of note, this difference was more pronounced in
the subgroup of patients with a clinical follow-up of > 3
years (100.0 ± 16.6 vs. 56.3 ± 8.4 fmol/mg) for whom, as
a consequence, there was greater veracity for the nega-
tive biopsy finding to be correct (Table 1).
While Dkk-3 levels as a single marker distinguished
between prostate cancer and non-cancer on the basis of
TRUS biopsies in the study cohort with a similar diag-
nostic accuracy compared with serum PSA (SP Dkk-3:
AUC = 0.633; serum PSA: AUC = 0.644), the diagnostic
accuracy of SP Dkk-3 levels was enhanced in multivari-
ate models including serum PSA (model A) and both,
serum and SP PSA levels (model B). Neither SP Dkk-3
nor SP PSA levels correlated with biopsy Gleason scores.
However, this might be in part due to the patient cohort
characteristics with approximately 2/3 of all positive
biopsies reported as Gleason 7 (either Gleason 3+4 or
Gleason 4+3). Of interest SP Dkk-3 negatively correlated
with SP PSA levels in the positive biopsy cohorts, which
might be responsible for the higher accuracy of model B
compared with model A.
The biological significance of the increase in SP Dkk-3
levels in patients with positive vs. negative PCa biopsy
findings remains unclear. As expression of Dkk-3 in
secretory epithelial cells of the prostate is reduced in
both PCa [5,13,20] and BPH [13], one might have
expected a similar effect on SP Dkk-3 levels in patients
with both these conditions. However, it is conceivable
that the elevated Dkk-3 levels in PCa SP are derived from
the tumor neovasculature, where high levels of Dkk-3 are
produced [13]. Elevated serum PSA levels in PCa patients
are supposed to be primarily an effect of tissue degrada-
tion and thus increased tissue permeability while in nor-
mal/BPH tissue an intact basement membrane prevents
leakage [21]. Likewise, Dkk-3 as a secreted protein of
similar size (PSA protein backbone: 237 aminoacids;
Dkk-3 protein backbone: 329 aminoacids) might be able
to diffuse through the disorganized PCa tissue.
Due to the limited number of SP samples available,
especially from patients with long-term follow-up, it was
not useful to further stratify the biopsy confirmed PCa
patients according to their risk in order to more closely
investigate the SP Dkk-3 and SP PSA correlation within
this cohort.
Given the limited diagnostic accuracy of single mar-
kers including PSA, much effort has been made to
Table 3 Determination of diagnostic accuracy.
all patients clinical follow-up > 3 yr
AUC 95% CI AUC 95% CI
serum PSA 0.644 0.524 - 0.763 0.696 0.544 - 0.848
SP Dkk-3 0.633 0.512 - 0.754 0.667 0.509 - 0.825
SP PSA 0.565 0.439 - 0.690 0.562 0.394 - 0.730
model A 0.658 0.539 - 0.776 0.724 0.568 - 0.880
model B 0.710 0.597 - 0.824 0.777 0.638 - 0.917
Areas under the receiver operator characteristics curve for univariate test
variables and multivariate models.
AUC, area under the curve; CI confidence intervall; PSA, prostate-specific
antigen; SP, seminal plasma.
Table 4 Correlative associations between univariate test variables.
SP PSA serum PSA Age Gleason*
all neg pos all neg pos all neg pos
Cohort Variable r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
r
(p-value)
all patients SP Dkk-3 -0.276 -0.165 -0.417 -0.950 -0.212 -0.128 0.118 -0.010 0.220 0.019
(0.013) (0.301) (0.007) (0.400) (0.183) (0.432) (0.294) (0.950) (0.173) (0.906)
SP PSA 1 1 1 0.020 0.125 -0.068 -0.320 -0.107 0.037 0.114
(0.860) (0.437) (0.679) (0.777) (0.507) (0.822) (0.483)
serum PSA 0.020 0.125 -0.038 1 1 1 0.117 -0.107 0.024 0.336
(0.860) (0.437) (0.679) (0.298) (0.507) (0.884) (0.034)
clinical follow-up SP Dkk-3 -0.241 -0.104 -0.430 -0.100 -0.327 -0.174 0.080 -0.307 0.336 0.123
> 3 yr (0.054) (0.620) (0.026) (0.506) (0.111) (0.450) (0.596) (0.135) (0.137) (0.595)
SP PSA 1 1 1 0.043 0.219 -0.099 0.099 0.071 0.169 0.181
(0.777) (0.293) (0.668) (0.511) (0.844) (0.465) (0.431)
serum PSA -0.100 0.219 -0.099 1 1 1 0.085 0.312 0.018 0.491
(0.506) (0.293) (0.668) (0.572) (0.129) (0.938) (0.024)
SP, seminal plasma; PSA, prostate-specific antigen; neg, negative biopsy; pos, positive biopsy; r, correlation coefficient.
Correlations were calculated by Pearson correlation analysis except for *Spearman’s rank correlation analysis.
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sources including SP [22-24]. Our data demonstrate that
SP is a valuable and valid source for biomarkers of pro-
static disease. The most promising attempt to improve
PCa diagnosis appears the establishment of a set of indi-
vidual biomarkers. Thus, SP Dkk-3 should be considered
in a panel of markers such as prostate cancer antigen 3
(PCA3) and/or hepsin [25] to be evaluated in combina-
tion in future validation studies.
Conclusions
A newly established sensitive and specific IEMA for
Dkk-3 revealed significantly higher SP Dkk-3 levels in
men with biopsy confirmed PCa indicating its inclusion
in a PCa diagnostic marker panel. A multivariate model
based on SP Dkk-3 and serum PSA levels showed higher
diagnostic accuracy compared with the individual mar-
kers. Although mean SP PSA levels were not signifi-
cantly altered in PCa patients, a combination of all three
markers further improved results with the multivariate
model, indicating potential utility in determining and
integrating all three in a panel of biomarkers. However,
more research is necessary to validate that SP Dkk-3
represents a clinically applicable PCa biomarker, ideally
in a set of individual biomarkers.
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